Novavax, Inc (NVAX)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | PHARMACEUTICALS |
| SIC: | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| CEO: | Stanley C. Erck |
| Employees: | 1,990 |
| Web site: | novavax.com |
|
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD, 20878
240-268-2000
| |
| Date | Ratio |
|---|---|
| 2019-05-10 | 1:20 |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Novavax, Inc. focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial. NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate, is in Phase 3 clinical trial. ResVax is a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
Please log in first to see chart